Back to search
FDAFDA · Food and drugs·Recall number D-0541-2026

Liraglutide Injection, 18 mg/3 mL (6 mg/mL), Rx only, Manufactured for: Lupin Pharmaceuticals, Inc., Naples, FL 34108, Manufactured by: Lupin Limited, Nagpur 441108, INDIA, a) 2 Pens- NDC 70748-346-02; b) 3 Pens - NDC 70748-346-03.

Published May 27, 2026 · Recall initiated: April 24, 2026

Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Presence of particulate matter: a white thread-like structure in the cartridge

What to do

Voluntary: Firm initiated · Letter

Recall details

Brand
LIRAGLUTIDE
Manufacturer
Lupin Pharmaceuticals Inc.
Distributor
Nationwide within U.S
Lot
Lots: a) WB00097, WB00094, WB00088, Expires: Jul. 2027; WB00103, Expires: Oct. 2027; WC00016, Expires: Dec. 2027; b) WB00098, WB00092, WB00093, Expires: Jul. 2027; WB00104, WB00106, WB00105, Expires: Oct. 2027.
Risk classification
Class II
Area (FDA)
drug
Country
United States

Sell products like this?

Recalert watches your whole catalog for recalls like this one, automatically.

Start free — no card